Targeted Therapeutics in Cancer Treatment

摘要: Historically, chemotherapy used for the treatment of malignancy was restricted to cytotoxic agents. Perturbation DNA synthesis and events regulating cell division are primary targets traditional drugs, as outlined in a previous chapter. Unfortunately, not specific cancer cells; therefore, these medications result broad range toxic side effects due damage normal cells. The narrow therapeutic window drugs is quite troublesome, given that palliation goal oncology therapy. Recently, therapy has migrated use small molecules targeting intracellular tumor era “targeted therapy” heralded by approval antibodies Rituximab Trastuzumab relapsed or refractory low-grade follicular B-cell non-Hodgkin’s lymphoma Her2/Neu-positive metastatic breast cancer, respectively [1, 2]. molecule inhibitors pathways principle validated efficacy imatinib mesylate bcr/abl-positive chronic myelogenous leukemia gastrointestinal stromal tumors (GIST) [3, 4].